Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
J Neurochem. 2014 Jan;128(1):162-72. doi: 10.1111/jnc.12380. Epub 2013 Aug 21.
Leptin signaling has received considerable attention in the Alzheimer disease (AD) field. Within the past decade, the peptide hormone has been demonstrated to attenuate tau hyperphosphorylation in neuronal cells and to be modulated by amyloid-β. Moreover, a role in neuroprotection and neurogenesis within the hippocampus has been shown in animal models. To further characterize the association between leptin signaling and vulnerable regions in AD, we assessed the profile of leptin and the leptin receptor in AD and control patients. We analyzed leptin levels in CSF, and the concentration and localization of leptin and leptin receptor in the hippocampus. Significant elevations in leptin levels in both CSF and hippocampal tissue of AD patients, compared with age-matched control cases, indicate a physiological up-regulation of leptin in AD. However, the level of leptin receptor mRNA decreased in AD brain and the leptin receptor protein was localized to neurofibrillary tangles, suggesting a severe discontinuity in the leptin signaling pathway. Collectively, our results suggest that leptin resistance in the hippocampus may play a role in the characteristic changes associated with the disease. These findings are the first to demonstrate such dysregulated leptin-signaling circuitry and provide novel insights into the possible role of aberrant leptin signaling in AD. In this study, increased leptin was found in CSF and hippocampus in Alzheimer disease indicating its physiological up-regulation, yet leptin receptor mRNA was decreased and leptin receptor protein was localized to neurofibrillary tangles, suggesting a discontinuity in the leptin signaling pathway. The lack of leptin signaling within degenerating neurons may represent a novel neuronal leptin resistance in Alzheimer disease.
瘦素信号在阿尔茨海默病(AD)领域受到了相当多的关注。在过去的十年中,已经证明这种肽激素可以减弱神经元细胞中的 tau 过度磷酸化,并可以被淀粉样蛋白-β调节。此外,在动物模型中还显示出其在海马体中的神经保护和神经发生中的作用。为了进一步描述瘦素信号与 AD 易损区域之间的关系,我们评估了 AD 和对照患者中瘦素和瘦素受体的特征。我们分析了 CSF 中的瘦素水平,以及海马体中瘦素和瘦素受体的浓度和定位。与年龄匹配的对照组相比,AD 患者的 CSF 和海马组织中的瘦素水平显著升高,表明 AD 中瘦素的生理上调。然而,AD 大脑中的瘦素受体 mRNA 水平降低,瘦素受体蛋白定位于神经原纤维缠结,表明瘦素信号通路严重中断。总的来说,我们的结果表明,海马体中的瘦素抵抗可能在与疾病相关的特征变化中发挥作用。这些发现首次证明了这种失调的瘦素信号通路,并为异常瘦素信号在 AD 中的可能作用提供了新的见解。在这项研究中,阿尔茨海默病患者的 CSF 和海马体中发现了增加的瘦素,表明其生理上调,然而瘦素受体 mRNA 减少,瘦素受体蛋白定位于神经原纤维缠结,表明瘦素信号通路中断。在变性神经元中缺乏瘦素信号可能代表阿尔茨海默病中新型的神经元瘦素抵抗。